Gilead Sciences completes Tubulis acquisition for $5bn
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
Drug Development
Concept Life Sciences and OpenBench partner on drug discovery services
FUJIFILM opens new iPSC facility in Madison, US
BMS and Anthropic collaborate for Claude implementation
QIAGEN and NVIDIA partner on AI drug discovery
SERB signs agreement to acquire Idefirix rights for $133.6m
VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
